ATM and acute myeloid leukemia: The triple combination of niraparib, decitabine and histone deacetylase inhibitors (HDACi) also showed a synergistic effect on AML cell lines (FLT3-ITD cells MOLM-14) with activation of the ATM pathway, increased production of ROS, decreased mitochondrial membrane potential, and induction of apoptosis.